Denali Therapeutics, Inc. (DNLI)
18.41
-0.25
(-1.34%)
USD |
NASDAQ |
Oct 23, 16:00
18.40
0.00 (0.00%)
After-Hours: 20:00
Denali Therapeutics Enterprise Value : 2.268B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.268B |
| October 22, 2026 | 2.308B |
| October 21, 2026 | 2.311B |
| October 20, 2026 | 2.351B |
| October 19, 2026 | 2.209B |
| October 16, 2026 | 2.141B |
| October 15, 2026 | 2.257B |
| October 14, 2026 | 2.182B |
| October 13, 2026 | 2.267B |
| October 12, 2026 | 2.355B |
| October 09, 2026 | 2.434B |
| October 08, 2026 | 2.310B |
| October 07, 2026 | 2.388B |
| October 06, 2026 | 2.407B |
| October 05, 2026 | 2.508B |
| October 02, 2026 | 2.522B |
| October 01, 2026 | 2.607B |
| September 30, 2026 | 2.629B |
| September 29, 2026 | 2.652B |
| September 28, 2026 | 2.679B |
| September 25, 2026 | 2.585B |
| September 24, 2026 | 2.597B |
| September 23, 2026 | 2.596B |
| September 22, 2026 | 2.778B |
| September 21, 2026 | 2.597B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.478B |
| September 17, 2026 | 2.543B |
| September 16, 2026 | 2.532B |
| September 15, 2026 | 2.583B |
| September 14, 2026 | 2.717B |
| September 11, 2026 | 2.696B |
| September 10, 2026 | 2.746B |
| September 09, 2026 | 2.773B |
| September 08, 2026 | 2.855B |
| September 04, 2026 | 2.887B |
| September 03, 2026 | 2.970B |
| September 02, 2026 | 2.978B |
| September 01, 2026 | 3.044B |
| August 31, 2026 | 3.123B |
| August 28, 2026 | 3.161B |
| August 27, 2026 | 3.268B |
| August 26, 2026 | 3.252B |
| August 25, 2026 | 3.310B |
| August 24, 2026 | 3.193B |
| August 21, 2026 | 3.308B |
| August 20, 2026 | 3.313B |
| August 19, 2026 | 3.431B |
| August 18, 2026 | 3.211B |
| August 17, 2026 | 3.217B |
| August 14, 2026 | 3.225B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -127.55M |
| Revenue (Quarterly) | 3.604M |
| Total Expenses (Quarterly) | 131.16M |
| EPS Diluted (Quarterly) | -0.681 |
| Gross Profit Margin (Quarterly) | -52.39% |
| Profit Margin (Quarterly) | -3.54K% |
| Earnings Yield | -15.41% |
| Normalized Earnings Yield | -15.41 |